Contineum Therapeutics, Inc. Income Statement

Income Statement Dec2023 Dec2024
Revenue & cost
Revenue 50.00M
Gross Profit 50.00M
Operating items
Research & Development 27.60M38.42M
Selling, General & Administrative 6.32M12.47M
Operating Expenses 33.92M50.89M
Operating Income 16.08M-50.89M
EBIT 16.08M-50.89M
Non-operating items
Interest & Investment Income 4.61M8.90M
Other Non Operating Income -0.18M1.02M
Non Operating Income 7.09M8.64M
Net income details
EBT 23.17M-42.26M
Tax Provisions 0.45M
Profit After Tax 22.72M-42.30M
Income from Continuing Operations 22.72M-42.26M
Consolidated Net Income 22.72M-42.26M
Income towards Parent Company 22.72M-42.26M
Net Income towards Common Stockholders 22.72M-42.26M
Additional items
EPS (Basic) 0.00M-0.00M
EPS (Weighted Average and Diluted) 0.00M-0.00M
Shares Outstanding (Weighted Average) 18.26M25.78M
EBITDA 22.90M-42.30M
Shares Outstanding 15.91M25.85M
Tax Rate 0.00M